Algernon Pharmaceuticals Inc. (CSE: AGN)

Algernon Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Selling, General & Admin	1.42	1.37	2.68	2.92	2.25	2.6
Research & Development	0.52	0.65	1.1	2.29	4.8	2.68
Operating Expenses	2.16	2.31	5.03	5.74	7.88	8.45
Operating Income	-2.16	-2.31	-5.03	-5.74	-7.88	-8.45
Interest & Investment Income	0	0	0	0	0.01	0.04
Other Non Operating Income (Expenses)	-0.12	-0.11	-0.21	-0.23	-0.17	-0.21
EBT Excluding Unusual Items	-2.27	-2.41	-5.24	-5.97	-8.04	-8.63
Gain (Loss) on Sale of Assets	1.66	1.66	-	-	-	-0
Asset Writedown	-	-	-1.54	-0.04	-	-0.05
Other Unusual Items	0.25	0.25	-	-0.05	0.31	0.14
Pretax Income	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54
Net Income	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54
Net Income to Common	-0.36	-0.5	-6.78	-6.05	-7.73	-8.54
Shares Outstanding (Basic)	23	20	15	7	6	4
Shares Outstanding (Diluted)	23	20	15	7	6	4
Shares Change (YoY)	37.20%	32.35%	117.87%	11.59%	76.84%	97.19%
EPS (Basic)	-0.02	-0.03	-0.45	-0.87	-1.24	-2.42
EPS (Diluted)	-0.02	-0.03	-0.45	-0.87	-1.24	-2.42
Free Cash Flow	-2.9	-2.71	-2.55	-2.91	-7.82	-6.61
Free Cash Flow Per Share	-0.13	-0.14	-0.17	-0.42	-1.26	-1.88
EBITDA	-2.13	-2.28	-4.98	-5.71	-	-8.42
D&A For EBITDA	0.02	0.03	0.05	0.03	-	0.03
EBIT	-2.16	-2.31	-5.03	-5.74	-7.88	-8.45

Source: S&P Capital IQ. Standard template. Financial Sources.